ServiceEdinburgh, Scotland, UKFounded 2016· One of 1986 Service companies tracked by AMPulse
Provides contract research, product development, and stem cell culture training using 3D bioprinting for drug testing and regenerative medicine applications.
CEO / Founder
Aidan Courtney
Team Size
11-50
Stage
Acquired
Total Funding
$5.6M
Key Investors
Innovate UK; University of Edinburgh; Scottish National Blood Transfusion Service; Scottish Enterprise
Technology & Products
Key Products
iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery
Technological Advantage
Proprietary valve-based bioprinting process tailored for delicate hESCs, developed in collaboration with Heriot-Watt University, allowing precise deposition of living cells that survive printing and retain differentiation potential.
Differentiation
Value Proposition
Enables pharmaceutical and biotech companies to accelerate drug discovery and toxicity testing by providing 3D-printed human stem cell tissues that mimic in vivo conditions, reducing reliance on animal models and improving predictive accuracy.
How They Differentiate
Part of Censo Biotechnologies (formed by merger of Roslin Cellab and Roslin Cell Sciences in 2016), specializing in iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery with Innovate UK backing, differentiating from broader bioprinting companies like CELLINK.
Market & Competition
Target Customers
Academic and commercial clients in life sciences, biotechnology, and pharmaceutical sectors
Industry Verticals
Life Sciences; Biotechnology; Pharmaceuticals
Competitors
CELLINK, Axol Bioscience
Growth & Milestones
Growth Metrics
Merged with Roslin Cell Sciences in 2016 to form Censo Biotechnologies Group; Received £117,432 in grant funding for a liver cell project; Over 190,000 people reached through media coverage of 3D bioprinting work
Major Milestones
2013: World-first 3D printing of human embryonic stem cells in collaboration with Heriot-Watt University; 2016: Merged with Roslin Cell Sciences to form Censo Biotechnologies
Roslin Cellab provides contract research, product development, and stem cell culture training centered on 3D bioprinting for drug testing and regenerative medicine. The company targets pharmaceutical and biotech clients seeking more predictive in vitro models to accelerate drug discovery and toxicity testing. Its core offering includes iPSC-based neuroscience, immune cell, and cardiac modeling, which aim to mimic in vivo conditions more closely than traditional 2D cultures.
The company's technological foundation is a proprietary valve-based bioprinting process developed in collaboration with Heriot-Watt University. This technique is tailored for delicate human embryonic stem cells (hESCs), enabling precise deposition of living cells that retain viability and pluripotency after printing. In 2013, Roslin Cellab achieved what it claims as the world-first 3D printing of hESCs, a milestone that underpins its ability to create complex tissue structures for drug screening.
Roslin Cellab serves academic and commercial clients in the life sciences, biotechnology, and pharmaceutical sectors. Named customers include Reinnervate Ltd and BioCision. The company is part of Censo Biotechnologies, formed by its 2016 merger with Roslin Cell Sciences, and has received backing from Innovate UK, the University of Edinburgh, and Scottish Enterprise. Total disclosed funding is £4.44 million.
Competitors include CELLINK and Axol Bioscience. Roslin Cellab differentiates through its specialization in iPSC-based neuroscience, immune cell, and cardiac modeling, a narrower focus than broader bioprinting platforms. A key open question is whether its valve-based bioprinting approach can scale from research services to commercial production volumes demanded by pharmaceutical partners.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights